logo
logo

Versant Ventures Announces Acquisition Of Portfolio Company Vividion Therapeutics

Versant Ventures Announces Acquisition Of Portfolio Company Vividion Therapeutics

08/05/21, 5:40 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgsan diego
Versant Ventures today announced that portfolio company Vividion Therapeutics has been acquired by Bayer AG for $1.5 billion up front and up to $500 million in potential future milestone payments. This acquisition represents one of the largest transactions for a preclinical-stage biotechnology company.

Company Info

Company
Versant Ventures
Company info
Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $4.2 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 85 Versant companies have achieved successful acquisitions or IPOs. For more information, please visit www.versantventures.com.